Paid Clinical Trials - 82,000 Members & Growing

  • Sponsored Links
  • About Us
  • Auto-Updates
  • FAQ's
  • Quick Start Guide
www.GlobalTestMarket.com

 

Find Paid Clinical Trials Join Paid Clinical Trials ...

PaidClinicalTrials.org is a registry of compensated and uncompensated, federally and privately supported clinical trials conducted in the United States and around the world. Here you will find information about a trial's purpose, who may participate, locations, and phone numbers.

 

Find Paid Clinical Trials Clinical Trial Seekers - PCT is a public service, sponsor supported, clinical trial database that may be accessed by the general public at no charge in accordance with our terms of service use.

Clinical trials are added and removed each day on a 30 day rotation. For accuracy - We only list clinical trials that have been reported to these government agencies in the last 30 days:

 

U.S. National Library of Medicine,
U.S. Department of Health & Human Services
U.S. National Institutes of health Services.







Paid Clinical Trials - Auto Update Service

If you would like to receive timely and important notifications about new clinical trials in your area please fill out this short form. There is never any cost for our notification services. We value your privacy, your email address and member information is NEVER shared!

*  Your Email Address:
*  Preferred Format:
    Title:
    First Name:
    Country:
    State (US):
    City (UK):
    Territory (AU):

Tips for Finding Clinical Trials

 

One of the toughest and most-time consuming parts for medical research staff conducting the clinical trials is actually finding volunteers willing to participate. Research staff are looking for you! There are numerous ways to identify clinical trials looking for healthy human volunteers.

 

Trials are actively conducted by hospitals, universities, foundations, and contract research organizations (CROs, firms that conduct studies for big pharmaceutical and biotechnology companies). According to CISCRP, nearly 40% of these clinical trials can be learned about through media such as tv, radio, or printed ads. While finding studies through tv and radio ads might be difficult, you can actively scour the wanted section of your local newspapers to find trials.

Most local research clinics run ads for volunteers in the local newspaper, employment papers, on TV, and on the radio. They also post ads on Craigslist and on their own websites. Call them up as soon as you see something of interest. If the study is no longer recruiting volunteers, they might enter you in there database for future study participation.

 

Look up local research clinics in your phone book and ask (a) if they have any studies openly recruiting healthy volunteers and (b) if you could be entered into their volunteer database.

College campuses and major universities with research hospitals are also great places to find clinical trial. Schools of medicine, dentistry, and nursing, along with departments of psychology, sociology, and communications, at local universities, are always looking for willing volunteers for their experiments. Perform an internet search for the hospitals, schools, and departments on nearby campuses, then look for any section concerning clinical trials or research volunteers.


When searching for clinical trials on our website you will click on a Clinical Trial Information sheet like this example. Find Paid Clinical Trials Example Information Sheet. The first thing you should do is to see if the clinical trial is right for you. You can do this by quickly scanning the headings of the information sheet. These headings are highlighted on the left by blue icons as follows:


  >> Status of the Clinical Trial (This will appear at the top in red or green)


Purpose - This will briefly let you know about the clinical trial and how it is conducted.


Eligibility - This tells you age, gender and health status information. If you do not meet these eligibility requirement you should move to another clinical trial.


Contacts and Locations - This will list the locations the clinical trial is being conducted and it will usually list the contact person to call. Note - Even if your location is not listed you should call the clinical trial investigator. Sometimes their locations have not been updated or they are willing to pay time and travel expenses.


More Information - This will often give alternative contact people and other pertinent information about the trial.

These headings appear on the left side of the information sheet and are fairly self explanatory. Doing this will help you to quickly evaluate if the clinical trial is right for you.

 


 

Paid Clinical Trials Searching Tips

 

Paid Clinical Trials Check the Conditions Category - If you only search the "Locations" directory you are missing out on a lot of clinical trials. Trials that are listed by "Condition" usually have multiple locations and can add new locations as the study moves forward.

 

Paid Clinical Trials Register Your Profile with us. - You can post your location and condition in our personal clinical trials directory for FREE. This helps the research recruiters find you when the right trial becomes available. Register for Clinical Trials Here.

 

Paid Clinical Trials Call the Clinical Trial Recruiters - At the bottom of all the information sheets you will see a "Contact Information" heading. Many clinical trials can be conducted in remote locations and the recruiters can help you.

 

Paid Clinical Trials Subscribe to our Auto Update Service - By subscribing to our Auto Update Service you will receive automated emails informing you when new trials have opened in your area.


Browse Locations ... United States» ... Wisconsin» ... Madison







  • Condition:   Healthy Volunteers
    Intervention:   Drug: LY2623091
    Sponsor:   Eli Lilly and Company
    Not yet recruiting - verified September 2014

  • Condition:   Cat Allergy
    Interventions:   Biological: AMG 157;   Biological: Cat Immunotherapy;   Biological: Placebo for Cat Immunotherapy;   Biological: Placebo for AMG 157
    Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Immune Tolerance Network (ITN)
    Not yet recruiting - verified September 2014

  • Condition:   Healthy Volunteers
    Intervention:   Drug: Apremilast
    Sponsor:   Celgene Corporation
    Recruiting - verified September 2014

  • Condition:   Healthy Volunteers
    Intervention:   Drug: CC-122
    Sponsor:   Celgene Corporation
    Not yet recruiting - verified September 2014

  • Condition:   Asthma
    Interventions:   Drug: Alendronate;   Drug: Placebo
    Sponsors:   Milton S. Hershey Medical Center;   National Heart, Lung, and Blood Institute (NHLBI)
    Not yet recruiting - verified August 2014

  • Condition:   Healthy
    Interventions:   Drug: BIIB061;   Other: Placebo
    Sponsor:   Biogen Idec
    Not yet recruiting - verified August 2014

  • Condition:   Chronic Heart Failure With Reduced Ejection Fraction.
    Intervention:   Drug: LCZ696
    Sponsors:   Novartis Pharmaceuticals;   Novartis
    Not yet recruiting - verified August 2014

  • Condition:   Rheumatoid Arthritis
    Interventions:   Drug: BMS-986104;   Drug: Placebo
    Sponsor:   Bristol-Myers Squibb
    Recruiting - verified August 2014

  • Condition:   Epilepsy
    Interventions:   Drug: Topiramate;   Drug: Levetiracetam
    Sponsor:   Janssen Research & Development, LLC
    Not yet recruiting - verified September 2014

  • Conditions:   Recurrent Bladder Cancer;   Stage I Bladder Cancer;   Stage II Bladder Cancer;   Stage III Bladder Cancer
    Interventions:   Drug: erlotinib hydrochloride;   Other: placebo;   Procedure: therapeutic conventional surgery;   Other: pharmacological study;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Not yet recruiting - verified July 2014

  • Condition:   Chronic Hepatitis C Virus (HCV) Infection Genotype 1
    Interventions:   Drug: ABT-450/r/ABT-267;   Drug: ABT-333;   Drug: Ribavirin (RBV)
    Sponsor:   AbbVie
    Recruiting - verified September 2014

  • Condition:   Breast Cancer
    Interventions:   Drug: 5-fluorouracil;   Drug: cyclophosphamide;   Drug: cyclophosphamide;   Drug: docetaxel;   Drug: doxorubicin;   Drug: epirubicin;   Drug: paclitaxel;   Drug: pertuzumab [Perjeta];   Drug: trastuzumab [Herceptin]
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified August 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Daratumumab;   Drug: VELCADE (Bortezomib);   Drug: Dexamethasone
    Sponsor:   Janssen Research & Development, LLC
    Not yet recruiting - verified September 2014

  • Conditions:   Brenner Tumor;   Ovarian Carcinosarcoma;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Papillary Serous Carcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer
    Interventions:   Drug: WEE1 inhibitor MK-1775;   Drug: gemcitabine hydrochloride;   Other: placebo;   Other: laboratory biomarker analysis;   Other: pharmacological study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified September 2014

  • Condition:   Ulcerative Colitis
    Interventions:   Drug: etrozulimab;   Drug: placebo
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified August 2014

  • Conditions:   Poliomyelitis;   Diphtheria;   Haemophilus Influenzae Type b;   Tetanus;   Acellular Pertussis;   Hepatitis B
    Interventions:   Biological: Infanrix hexa;   Biological: Pediarix;   Biological: ActHIB;   Biological: Pentacel;   Biological: Engerix-B;   Biological: Infanrix;   Biological: Hiberix;   Biological: Prevnar13;   Biological: Rotarix
    Sponsor:   GlaxoSmithKline
    Recruiting - verified September 2014

  • Conditions:   Stage I Prostate Cancer;   Stage IIA Prostate Cancer;   Stage IIB Prostate Cancer
    Interventions:   Drug: pomegranate-extract pill;   Other: placebo;   Other: laboratory biomarker analysis;   Other: pharmacological study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2014

  • Conditions:   Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
    Interventions:   Drug: clofarabine;   Drug: daunorubicin hydrochloride;   Other: clinical observation;   Drug: cytarabine;   Drug: decitabine;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment;   Other: questionnaire administration
    Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified September 2014

  • Condition:   Alzheimer's Disease
    Intervention:   Drug: T-817MA
    Sponsors:   Toyama Chemical Co., Ltd.;   Alzheimer's Disease Cooperative Study (ADCS)
    Recruiting - verified June 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Daratumumab;   Drug: Lenalidomide;   Drug: Dexamethasone
    Sponsor:   Janssen Research & Development, LLC
    Recruiting - verified September 2014

  • Condition:   Brain Ischemia
    Interventions:   Drug: alteplase [Activase];   Drug: alteplase placebo;   Drug: aspirin;   Drug: aspirin placebo
    Sponsor:   Genentech
    Recruiting - verified September 2014

  • Condition:   Asthma
    Interventions:   Biological: Benralizumab;   Biological: Placebo;   Biological: Benralizumab
    Sponsor:   AstraZeneca
    Recruiting - verified September 2014

  • Condition:   Magnetic Resonance Imaging
    Interventions:   Drug: Gadoxetate disodium (Eovist/Primovist, BAY 86-4873);   Drug: Sodium chloride solution
    Sponsor:   Bayer
    Not yet recruiting - verified September 2014

  • Condition:   Chronic Heart Failure
    Interventions:   Biological: Allogeneic Mesenchymal Precursor Cells (MPC);   Other: Sham Comparator
    Sponsor:   Teva Pharmaceutical Industries
    Recruiting - verified September 2014

  • Condition:   Down Syndrome
    Interventions:   Drug: Placebo;   Drug: RG1662;   Drug: RG1662
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified August 2014

  • Condition:   Non-Small Cell Lung Cancer
    Intervention:   Drug: MPDL3280A
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified September 2014

  • Condition:   Short Bowel Syndrome
    Intervention:  
    Sponsor:   NPS Pharmaceuticals
    Recruiting - verified September 2014

  • Conditions:   Idiopathic Pulmonary Fibrosis;   Gastroesophageal Reflux
    Intervention:   Procedure: Surgery
    Sponsors:   University of California, San Francisco;   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified September 2014

  • Conditions:   Stage II Childhood Anaplastic Large Cell Lymphoma;   Stage III Childhood Anaplastic Large Cell Lymphoma;   Stage IV Childhood Anaplastic Large Cell Lymphoma
    Interventions:   Drug: brentuximab vedotin;   Drug: crizotinib;   Drug: dexamethasone;   Drug: ifosfamide;   Drug: methotrexate;   Drug: cytarabine;   Drug: etoposide;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Condition:   COPD
    Interventions:   Drug: QBM076;   Drug: placebo
    Sponsors:   Novartis Pharmaceuticals;   Novartis
    Recruiting - verified August 2014

  • Condition:   2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer
    Interventions:   Biological: GVAX Pancreas Vaccine;   Biological: CRS-207;   Drug: gemcitabine, capecitabine, 5-FU, irinotecan or erlotinib;   Drug: cyclophosphamide
    Sponsor:   Aduro BioTech, Inc.
    Recruiting - verified September 2014

  • Condition:   Asthma
    Interventions:   Drug: Flovent Diskus® 100 mcg;   Drug: Flovent Diskus® 250 mcg;   Drug: Flovent Diskus® 500 mcg;   Drug: Advair Diskus® 100/50 mcg;   Drug: Advair Diskus® 250/50 mcg
    Sponsors:   Milton S. Hershey Medical Center;   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified August 2014

  • Conditions:   Pancreatic Neoplasms;   Digestive System Neoplasms;   Neoplasms by Site;   Neoplasms;   Endocrine Gland Neoplasms;   Pancreatic Diseases;   Digestive System Diseases;   Endocrine System Diseases;   Gemcitabine;   Antimetabolites, Antineoplastic
    Interventions:   Drug: nab-Paclitaxel 125 mg/m2;   Drug: gemcitabine 1000 mg/m2;   Drug: gemcitabine 1000 mg/m2
    Sponsor:   Celgene Corporation
    Recruiting - verified September 2014

  • Conditions:   Recurrent Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
    Interventions:   Biological: bevacizumab;   Biological: ipilimumab;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified August 2014

  • Condition:   Crohn's Disease
    Interventions:   Drug: RHB-104;   Drug: Placebo
    Sponsor:   RedHill Biopharma Limited
    Recruiting - verified December 2013

  • Condition:   Prostatic Neoplasms
    Interventions:   Drug: ARN-509;   Drug: Placebo
    Sponsor:   Aragon Pharmaceuticals, Inc.
    Recruiting - verified September 2014

  • Condition:   Age-Related Macular Degeneration
    Interventions:   Drug: E10030;   Drug: ranibizumab;   Drug: E10030 sham intravitreal injection
    Sponsor:   Ophthotech Corporation
    Recruiting - verified August 2014

  • Condition:   Cancer of Kidney
    Intervention:   Device: Microwave pre-coagulation
    Sponsor:   University of Wisconsin, Madison
    Recruiting - verified August 2014

  • Conditions:   Depressive Disorder;   Bipolar Disorder;   Suicide;   Suicide, Attempted
    Interventions:   Drug: Lithium;   Drug: Placebo
    Sponsor:   Department of Veterans Affairs
    Not yet recruiting - verified September 2014

  • Condition:   Acute Hematogenous Osteomyelitis
    Interventions:   Drug: Daptomycin;   Drug: Vancomycin;   Drug: nafcillin
    Sponsor:   Cubist Pharmaceuticals
    Recruiting - verified August 2014

  • Condition:   Epilepsy
    Interventions:   Drug: Lacosamide;   Other: Placebo
    Sponsor:   UCB Pharma
    Recruiting - verified August 2014

  • Condition:   Asthma
    Interventions:   Biological: Benralizumab;   Biological: Placebo;   Biological: Benralizumab (adolescent patients in the EU)
    Sponsor:   AstraZeneca
    Recruiting - verified August 2014

  • Condition:   Diabetic Macular Edema
    Interventions:   Procedure: Prompt Laser;   Drug: Prompt aflibercept;   Procedure: Deferred laser;   Drug: Deferred aflibercept
    Sponsors:   Diabetic Retinopathy Clinical Research Network;   Regeneron Pharmaceuticals
    Recruiting - verified August 2014

  • Conditions:   Hepatic Complications;   Renal Failure;   Unspecified Adult Solid Tumor, Protocol Specific
    Interventions:   Drug: dabrafenib;   Other: pharmacological study;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified September 2014

  • Condition:   Non Small Cell Lung Cancer (NSCLC)
    Interventions:   Biological: pembrolizumab;   Drug: Docetaxel
    Sponsor:   Merck Sharp & Dohme Corp.
    Recruiting - verified September 2014

  • Condition:   Basal Cell Carcinoma
    Interventions:   Drug: Placebo;   Drug: vismodegib
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified August 2014

  • Condition:   Indolent Non-Hodgkin's Lymphoma
    Interventions:   Biological: Arm A: Rituximab;   Biological: Arm B: GA101
    Sponsors:   PrECOG, LLC.;   Genentech
    Recruiting - verified September 2014

  • Conditions:   Acute Lung Injury;   Adult Respiratory Distress Syndrome
    Interventions:   Other: Low-tidal-volume ventilation;   Other: Airway Pressure Release Ventilation (APRV)
    Sponsor:   University of Wisconsin, Madison
    Recruiting - verified August 2014

  • Conditions:   Advanced Castrate-resistant Prostate Cancer (CRPC);;   Squamous Non-Small Cell Lung Cancer (sqNSCLC);;   Triple Negative Breast Cancer (TNBC)
    Intervention:   Drug: AZD8186
    Sponsor:   AstraZeneca
    Recruiting - verified August 2014

  • Conditions:   Stage IB Breast Cancer;   Stage II Breast Cancer
    Interventions:   Radiation: regional nodal XRT;   Radiation: chestwall XRT;   Radiation: WBI
    Sponsors:   NSABP Foundation Inc;   National Cancer Institute (NCI);   Radiation Therapy Oncology Group
    Recruiting - verified September 2014

  • Condition:   Asthma
    Interventions:   Drug: lebrikizumab;   Drug: lebrikizumab;   Drug: placebo
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified August 2014

  • Conditions:   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma
    Interventions:   Drug: lenalidomide;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: vincristine sulfate;   Drug: prednisone;   Other: laboratory biomarker analysis;   Procedure: positron emission tomography
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2014

  • Conditions:   Newly Diagnosed;   Advanced Ovarian Cancer;   FIGO Stage III-IV;   BRCA Mutation;   Complete Response;   Partial Response;   First Line Platinum Chemotherapy
    Intervention:   Drug: Olaparib 300mg tablets
    Sponsors:   AstraZeneca;   Gynecologic Oncology Group (GOG);   Myriad Genetics - BRACAnalysis test for FDA Premarket Approval (PMA)
    Recruiting - verified September 2014

  • Conditions:   Ovarian Neoplasms;   Peritoneal Neoplasms;   Fallopian Tube Neoplasms
    Interventions:   Drug: Trabectedin;   Drug: DOXIL;   Drug: Dexamethasone;   Drug: DOXIL
    Sponsors:   Janssen Research & Development, LLC;   PharmaMar
    Recruiting - verified September 2014

  • Conditions:   Metastatic Gastrointestinal Carcinoid Tumor;   Pulmonary Carcinoid Tumor;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Neuroendocrine Carcinoma of the Skin;   Regional Gastrointestinal Carcinoid Tumor;   Stage III Neuroendocrine Carcinoma of the Skin;   Stage IV Neuroendocrine Carcinoma of the Skin;   Thyroid Gland Medullary Carcinoma
    Interventions:   Drug: pazopanib hydrochloride;   Other: placebo;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified April 2014

  • Conditions:   Pancreatic Cancer;   Pancreatic Carcinoma Non-resectable;   Locally Advanced Malignant Neoplasm
    Interventions:   Drug: FOLFIRINOX;   Biological: Algenpantucel-L Immunotherapy;   Radiation: 5-FU Chemoradiation;   Drug: Gemcitabine;   Drug: Capecitabine;   Drug: Nab-Paclitaxel
    Sponsor:   NewLink Genetics Corporation
    Recruiting - verified August 2014

  • Conditions:   Ciliary Body and Choroid Melanoma, Medium/Large Size;   Ciliary Body and Choroid Melanoma, Small Size;   Iris Melanoma;   Metastatic Intraocular Melanoma;   Recurrent Intraocular Melanoma;   Stage IIIA Intraocular Melanoma;   Stage IIIB Intraocular Melanoma;   Stage IIIC Intraocular Melanoma;   Stage IV Intraocular Melanoma
    Interventions:   Drug: cabozantinib-s-malate;   Drug: temozolomide;   Drug: dacarbazine;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified September 2014

  • Condition:   Juvenile Myelomonocytic Leukemia
    Interventions:   Drug: busulfan;   Drug: cyclophosphamide;   Drug: melphalan;   Drug: fludarabine phosphate;   Procedure: allogeneic hematopoietic stem cell transplantation;   Drug: tacrolimus;   Drug: mycophenolate mofetil;   Other: pharmacological study;   Other: laboratory biomarker analysis
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified September 2014

  • Condition:   Pulmonary Arterial Hypertension
    Intervention:   Drug: Macitentan
    Sponsor:   Actelion
    Recruiting - verified September 2014

  • Condition:   Acute Myeloid Leukemia
    Interventions:   Drug: Midostaurin (PKC412);   Other: Standard of Care
    Sponsors:   Novartis Pharmaceuticals;   Novartis
    Recruiting - verified September 2014

  • Condition:   Posttraumatic Stress Disorder (PTSD)
    Interventions:   Behavioral: Individual Placement & Support;   Behavioral: VA Transitional Work Program
    Sponsor:   Department of Veterans Affairs
    Recruiting - verified September 2014

  • Condition:   Kidney Transplantation
    Interventions:   Drug: Belatacept;   Drug: Tacrolimus;   Drug: Cyclosporine
    Sponsor:   Bristol-Myers Squibb
    Recruiting - verified September 2014

  • Conditions:   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Mantle Cell Lymphoma;   Follicular Lymphoma;   Diffuse Large B-cell Lymphoma
    Intervention:   Drug: PCI-32765 (Ibrutinib)
    Sponsors:   Janssen Research & Development, LLC;   Pharmacyclics
    Recruiting - verified September 2014

  • Condition:   Osteoporosis
    Interventions:   Drug: odanacatib;   Other: placebo to odanacatib
    Sponsor:   Merck Sharp & Dohme Corp.
    Recruiting - verified August 2014

  • Conditions:   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
    Interventions:   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: idarubicin hydrochloride;   Drug: vorinostat;   Procedure: allogeneic hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified September 2014

  • Conditions:   Adult Grade III Lymphomatoid Granulomatosis;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Childhood Burkitt Lymphoma;   Childhood Diffuse Large Cell Lymphoma;   Childhood Grade III Lymphomatoid Granulomatosis;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Contiguous Stage II Adult Burkitt Lymphoma;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Contiguous Stage II Marginal Zone Lymphoma;   Contiguous Stage II Small Lymphocytic Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Progressive Hairy Cell Leukemia, Initial Treatment;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage 0 Chronic Lymphocytic Leukemia;   Stage I Adult Burkitt Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Diffuse Small Cleaved Cell Lymphoma;   Stage I Adult Hodgkin Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Adult T-cell Leukemia/Lymphoma;   Stage I Childhood Anaplastic Large Cell Lymphoma;   Stage I Childhood Hodgkin Lymphoma;   Stage I Childhood Large Cell Lymphoma;   Stage I Childhood Lymphoblastic Lymphoma;   Stage I Childhood Small Noncleaved Cell Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Small Lymphocytic Lymphoma;   Stage IA Mycosis Fungoides/Sezary Syndrome;   Stage IB Mycosis Fungoides/Sezary Syndrome;   Stage II Adult Hodgkin Lymphoma;   Stage II Adult T-cell Leukemia/Lymphoma;   Stage II Childhood Anaplastic Large Cell Lymphoma;   Stage II Childhood Hodgkin Lymphoma;   Stage II Childhood Large Cell Lymphoma;   Stage II Childhood Lymphoblastic Lymphoma;   Stage II Childhood Small Noncleaved Cell Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IIA Mycosis Fungoides/Sezary Syndrome;   Stage IIB Mycosis Fungoides/Sezary Syndrome;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Adult T-cell Leukemia/Lymphoma;   Stage III Childhood Anaplastic Large Cell Lymphoma;   Stage III Childhood Hodgkin Lymphoma;   Stage III Childhood Large Cell Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage III Childhood Small Noncleaved Cell Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Small Lymphocytic Lymphoma;   Stage IIIA Mycosis Fungoides/Sezary Syndrome;   Stage IIIB Mycosis Fungoides/Sezary Syndrome;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Adult T-cell Leukemia/Lymphoma;   Stage IV Childhood Anaplastic Large Cell Lymphoma;   Stage IV Childhood Hodgkin Lymphoma;   Stage IV Childhood Large Cell Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Stage IV Childhood Small Noncleaved Cell Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Small Lymphocytic Lymphoma;   Stage IVA Mycosis Fungoides/Sezary Syndrome;   Stage IVB Mycosis Fungoides/Sezary Syndrome;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia;   Untreated Hairy Cell Leukemia;   Waldenström Macroglobulinemia
    Interventions:   Other: questionnaire administration;   Other: laboratory biomarker analysis
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI);   The Leukemia and Lymphoma Society
    Recruiting - verified September 2014

  • Conditions:   Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
    Interventions:   Drug: dinaciclib;   Drug: Akt inhibitor MK2206;   Other: pharmacological study;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Conditions:   Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Recurrent Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
    Interventions:   Drug: Akt inhibitor MK2206;   Drug: anastrozole;   Drug: goserelin acetate;   Procedure: neoadjuvant therapy;   Procedure: therapeutic conventional surgery;   Other: laboratory biomarker analysis;   Other: pharmacological study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified August 2014

  • Condition:   Long-term Safety of TIP
    Intervention:   Drug: TBM100
    Sponsors:   Novartis Pharmaceuticals;   Novartis
    Recruiting - verified August 2014

  • Condition:   Idiopathic Pulmonary Fibrosis
    Interventions:   Drug: BMS-986020;   Drug: Placebo matching with BMS-986020
    Sponsor:   Bristol-Myers Squibb
    Recruiting - verified September 2014

  • Condition:   Recurrent Neuroblastoma
    Interventions:   Drug: temozolomide;   Drug: irinotecan hydrochloride;   Drug: temsirolimus;   Biological: dinutuximab;   Biological: sargramostim;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified August 2014

  • Condition:   Dyslipidemia
    Interventions:   Biological: Evolocumab (AMG 145);   Other: Placebo;   Drug: Effective statin therapy
    Sponsor:   Amgen
    Recruiting - verified September 2014

  • Conditions:   Non-small Cell Lung Cancer;   Progression of Non-small Cell Lung Cancer;   Non-small Cell Lung Cancer Recurrent
    Interventions:   Drug: Docetaxel;   Biological: HyperAcute®-Lung Immunotherapy;   Drug: Gemcitabine;   Drug: Pemetrexed
    Sponsor:   NewLink Genetics Corporation
    Recruiting - verified August 2014

  • Condition:   Alzheimer's Disease
    Interventions:   Drug: MK-8931 (Part I and Part II);   Drug: Placebo (Part I);   Drug: MK-8931 (Part II)
    Sponsor:   Merck Sharp & Dohme Corp.
    Recruiting - verified September 2014

  • Conditions:   Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma;   Recurrent Melanoma;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Non-small Cell Lung Cancer;   Recurrent Renal Cell Cancer;   Recurrent Salivary Gland Cancer;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Stage III Renal Cell Cancer;   Stage III Salivary Gland Cancer;   Stage III Squamous Cell Carcinoma of the Hypopharynx;   Stage III Squamous Cell Carcinoma of the Larynx;   Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage III Squamous Cell Carcinoma of the Nasopharynx;   Stage III Squamous Cell Carcinoma of the Oropharynx;   Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage III Verrucous Carcinoma of the Larynx;   Stage III Verrucous Carcinoma of the Oral Cavity;   Stage IIIA Melanoma;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Melanoma;   Stage IIIB Non-small Cell Lung Cancer;   Stage IIIC Melanoma;   Stage IV Melanoma;   Stage IV Non-small Cell Lung Cancer;   Stage IV Renal Cell Cancer;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IVA Salivary Gland Cancer;   Stage IVA Squamous Cell Carcinoma of the Larynx;   Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Verrucous Carcinoma of the Larynx;   Stage IVA Verrucous Carcinoma of the Oral Cavity;   Stage IVB Salivary Gland Cancer;   Stage IVB Squamous Cell Carcinoma of the Larynx;   Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Oropharynx;   Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Verrucous Carcinoma of the Larynx;   Stage IVB Verrucous Carcinoma of the Oral Cavity;   Stage IVC Salivary Gland Cancer;   Stage IVC Squamous Cell Carcinoma of the Larynx;   Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVC Squamous Cell Carcinoma of the Oropharynx;   Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Verrucous Carcinoma of the Larynx;   Stage IVC Verrucous Carcinoma of the Oral Cavity;   Tongue Cancer
    Interventions:   Biological: recombinant interleukin-15;   Other: pharmacological study;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified April 2014

  • Condition:   Dietary Modification
    Interventions:   Other: Broccoli and Brussels Sprouts;   Dietary Supplement: Cruciferous Complete;   Other: Placebo
    Sponsors:   University of Wisconsin, Madison;   Standard Process Inc.
    Recruiting - verified August 2014

  • Conditions:   Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
    Interventions:   Biological: ipilimumab;   Biological: recombinant interferon alfa-2b;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified April 2014

  • Condition:   Prostate Cancer
    Interventions:   Biological: sipuleucel-T;   Biological: DNA Vaccine
    Sponsors:   University of Wisconsin, Madison;   Dendreon
    Recruiting - verified August 2014

  • Conditions:   Rubella;   Measles;   Mumps
    Interventions:   Biological: GSK Biologicals measles, mumps and rubella vaccine live (GSK 209762).;   Biological: Merck & Co., Inc.'s M-M-R®II (also called M-M-R Vax Pro®), combined measles-mumps-rubella virus vaccine.;   Biological: Varivax® (Merck & Co., Inc.);   Biological: Havrix®;   Biological: Prevnar 13® (Pfizer Inc.)
    Sponsor:   GlaxoSmithKline
    Recruiting - verified September 2014

  • Conditions:   Intestinal Barrier Function;   Chronic Inflammation
    Interventions:   Other: Low fat dairy yogurt;   Other: Soy pudding
    Sponsors:   University of Wisconsin, Madison;   Dairy Research Institute
    Recruiting - verified September 2014

  • Condition:   Ischemic Dilated Cardiomyopathy (IDCM)
    Interventions:   Biological: ixmyelocel-T;   Other: Vehicle Control
    Sponsor:   Aastrom Biosciences
    Recruiting - verified September 2014

  • Condition:   Acute Respiratory Infection
    Interventions:   Other: Mindfulness Meditation;   Other: Exercise
    Sponsors:   University of Wisconsin, Madison;   National Center for Complementary and Alternative Medicine (NCCAM)
    Recruiting - verified September 2014

  • Conditions:   Extensive Stage Small Cell Lung Cancer;   Large Cell Lung Cancer;   Metastatic Carcinoma of Unknown Primary;   Neuroendocrine Carcinoma;   Newly Diagnosed Carcinoma of Unknown Primary;   Stage IV Non-small Cell Lung Cancer
    Interventions:   Drug: veliparib;   Other: placebo;   Drug: etoposide;   Drug: cisplatin;   Other: laboratory biomarker analysis;   Other: questionnaire administration;   Other: quality-of-life assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Condition:   Stage IV Pancreatic Cancer
    Interventions:   Drug: OMP-59R5;   Drug: Gemcitabine;   Drug: Placebo;   Drug: Nab-Paclitaxel
    Sponsor:   OncoMed Pharmaceuticals, Inc.
    Recruiting - verified August 2014

  • Conditions:   Adult Anaplastic Astrocytoma;   Adult Anaplastic Ependymoma;   Adult Anaplastic Oligodendroglioma;   Adult Brain Stem Glioma;   Adult Ependymoblastoma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Mixed Glioma;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Adult Pineal Gland Astrocytoma;   AIDS-related Diffuse Large Cell Lymphoma;   AIDS-related Diffuse Mixed Cell Lymphoma;   AIDS-related Diffuse Small Cleaved Cell Lymphoma;   AIDS-related Immunoblastic Large Cell Lymphoma;   AIDS-related Lymphoblastic Lymphoma;   AIDS-related Peripheral/Systemic Lymphoma;   AIDS-related Primary CNS Lymphoma;   AIDS-related Small Noncleaved Cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Anaplastic Thyroid Cancer;   Angioimmunoblastic T-cell Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extensive Stage Small Cell Lung Cancer;   Extra-adrenal Paraganglioma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Gastrinoma;   Glucagonoma;   Hepatic Complications;   Hepatosplenic T-cell Lymphoma;   HIV-associated Hodgkin Lymphoma;   Insular Thyroid Cancer;   Insulinoma;   Intraocular Lymphoma;   Male Breast Cancer;   Metastatic Gastrointestinal Carcinoid Tumor;   Metastatic Pheochromocytoma;   Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Pancreatic Polypeptide Tumor;   Peripheral T-cell Lymphoma;   Pulmonary Carcinoid Tumor;   Recurrent Adenoid Cystic Carcinoma of the Oral Cavity;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Brain Tumor;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Basal Cell Carcinoma of the Lip;   Recurrent Bladder Cancer;   Recurrent Breast Cancer;   Recurrent Colon Cancer;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Recurrent Islet Cell Carcinoma;   Recurrent Lymphoepithelioma of the Nasopharynx;   Recurrent Lymphoepithelioma of the Oropharynx;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Melanoma;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Recurrent Mucoepidermoid Carcinoma of the Oral Cavity;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Neuroendocrine Carcinoma of the Skin;   Recurrent Non-small Cell Lung Cancer;   Recurrent Pancreatic Cancer;   Recurrent Pheochromocytoma;   Recurrent Prostate Cancer;   Recurrent Rectal Cancer;   Recurrent Renal Cell Cancer;   Recurrent Salivary Gland Cancer;   Recurrent Small Cell Lung Cancer;   Recurrent Small Lymphocytic Lymphoma;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Thyroid Cancer;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Regional Gastrointestinal Carcinoid Tumor;   Regional Pheochromocytoma;   Small Intestine Lymphoma;   Somatostatinoma;   Splenic Marginal Zone Lymphoma;   Stage III Adenoid Cystic Carcinoma of the Oral Cavity;   Stage III Adult Soft Tissue Sarcoma;   Stage III Basal Cell Carcinoma of the Lip;   Stage III Bladder Cancer;   Stage III Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Stage III Follicular Thyroid Cancer;   Stage III Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Stage III Lymphoepithelioma of the Nasopharynx;   Stage III Lymphoepithelioma of the Oropharynx;   Stage III Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Stage III Mucoepidermoid Carcinoma of the Oral Cavity;   Stage III Neuroendocrine Carcinoma of the Skin;   Stage III Pancreatic Cancer;   Stage III Papillary Thyroid Cancer;   Stage III Prostate Cancer;   Stage III Renal Cell Cancer;   Stage III Salivary Gland Cancer;   Stage III Squamous Cell Carcinoma of the Hypopharynx;   Stage III Squamous Cell Carcinoma of the Larynx;   Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage III Squamous Cell Carcinoma of the Nasopharynx;   Stage III Squamous Cell Carcinoma of the Oropharynx;   Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage III Verrucous Carcinoma of the Larynx;   Stage III Verrucous Carcinoma of the Oral Cavity;   Stage IIIA Breast Cancer;   Stage IIIA Colon Cancer;   Stage IIIA Melanoma;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIA Rectal Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Melanoma;   Stage IIIB Non-small Cell Lung Cancer;   Stage IIIB Rectal Cancer;   Stage IIIC Breast Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Melanoma;   Stage IIIC Rectal Cancer;   Stage IV Adult Soft Tissue Sarcoma;   Stage IV Bladder Cancer;   Stage IV Breast Cancer;   Stage IV Lymphoepithelioma of the Nasopharynx;   Stage IV Melanoma;   Stage IV Neuroendocrine Carcinoma of the Skin;   Stage IV Non-small Cell Lung Cancer;   Stage IV Pancreatic Cancer;   Stage IV Prostate Cancer;   Stage IV Renal Cell Cancer;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IVA Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IVA Basal Cell Carcinoma of the Lip;   Stage IVA Colon Cancer;   Stage IVA Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Follicular Thyroid Cancer;   Stage IVA Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Lymphoepithelioma of the Oropharynx;   Stage IVA Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Mucoepidermoid Carcinoma of the Oral Cavity;   Stage IVA Papillary Thyroid Cancer;   Stage IVA Rectal Cancer;   Stage IVA Salivary Gland Cancer;   Stage IVA Squamous Cell Carcinoma of the Larynx;   Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Verrucous Carcinoma of the Larynx;   Stage IVA Verrucous Carcinoma of the Oral Cavity;   Stage IVB Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IVB Basal Cell Carcinoma of the Lip;   Stage IVB Colon Cancer;   Stage IVB Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Follicular Thyroid Cancer;   Stage IVB Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Lymphoepithelioma of the Oropharynx;   Stage IVB Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Mucoepidermoid Carcinoma of the Oral Cavity;   Stage IVB Papillary Thyroid Cancer;   Stage IVB Rectal Cancer;   Stage IVB Salivary Gland Cancer;   Stage IVB Squamous Cell Carcinoma of the Larynx;   Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Oropharynx;   Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Verrucous Carcinoma of the Larynx;   Stage IVB Verrucous Carcinoma of the Oral Cavity;   Stage IVC Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IVC Basal Cell Carcinoma of the Lip;   Stage IVC Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Follicular Thyroid Cancer;   Stage IVC Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Lymphoepithelioma of the Oropharynx;   Stage IVC Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Mucoepidermoid Carcinoma of the Oral Cavity;   Stage IVC Papillary Thyroid Cancer;   Stage IVC Salivary Gland Cancer;   Stage IVC Squamous Cell Carcinoma of the Larynx;   Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVC Squamous Cell Carcinoma of the Oropharynx;   Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Verrucous Carcinoma of the Larynx;   Stage IVC Verrucous Carcinoma of the Oral Cavity;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Thyroid Gland Medullary Carcinoma;   Tongue Cancer;   Unspecified Adult Solid Tumor, Protocol Specific;   Waldenström Macroglobulinemia
    Interventions:   Drug: romidepsin;   Other: pharmacological study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified August 2014

  • Condition:   Unspecified Adult Solid Tumor, Protocol Specific
    Interventions:   Drug: tivantinib;   Drug: temsirolimus;   Other: pharmacological study;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified September 2014

  • Conditions:   HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Tumors Metastatic to Brain
    Interventions:   Drug: lapatinib ditosylate;   Radiation: whole-brain radiation therapy
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Condition:   Breast Cancer
    Intervention:  
    Sponsor:   Genentech
    Recruiting - verified September 2014

  • Condition:   Asthma
    Intervention:  
    Sponsors:   Milton S. Hershey Medical Center;   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified August 2014

  • Condition:   Emphysema
    Intervention:   Device: RePneu Lung Volume Reduction Coil System
    Sponsor:   PneumRx, Inc.
    Recruiting - verified December 2012

  • Condition:   Epilepsy
    Intervention:   Drug: ezogabine/retigabine
    Sponsor:   GlaxoSmithKline
    Recruiting - verified September 2014

  • Condition:   Clostridium Difficile Infection
    Interventions:   Drug: CB-183,315;   Drug: oral vancomycin
    Sponsor:   Cubist Pharmaceuticals
    Recruiting - verified September 2014

  • Conditions:   B-cell Childhood Acute Lymphoblastic Leukemia;   Childhood Diffuse Large Cell Lymphoma;   L3 Childhood Acute Lymphoblastic Leukemia;   Stage III Childhood Large Cell Lymphoma;   Stage IV Childhood Large Cell Lymphoma;   Untreated Childhood Acute Lymphoblastic Leukemia
    Interventions:   Biological: rituximab;   Drug: prednisone;   Drug: etoposide;   Drug: doxorubicin hydrochloride;   Drug: cytarabine;   Drug: vincristine sulfate;   Drug: cyclophosphamide;   Drug: methotrexate;   Drug: methylprednisolone;   Drug: leucovorin calcium;   Drug: therapeutic hydrocortisone
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified September 2014

  • Condition:   Neoplasms, Hematologic
    Intervention:   Drug: 120 mg LY2784544
    Sponsor:   Eli Lilly and Company
    Recruiting - verified September 2014

  • Conditions:   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
    Interventions:   Drug: abiraterone acetate;   Drug: prednisone;   Drug: veliparib;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified September 2014

  • Condition:   Head and Neck Cancer
    Interventions:   Drug: MEHD7945A;   Drug: cetuximab
    Sponsor:   Genentech
    Recruiting - verified August 2014

  • Condition:   Smoking Cessation
    Interventions:   Drug: placebo;   Drug: varenicline tartrate;   Drug: bupropion hydrochloride;   Drug: Nicotine Replacement Therapy Patch
    Sponsor:   Pfizer
    Recruiting - verified September 2014

  • Conditions:   Asthma;   Chronic Obstructive Pulmonary Disease;   Obstructive Sleep Apnea
    Intervention:   Drug: Inhaled Fluticasone Propionate
    Sponsor:   Department of Veterans Affairs
    Recruiting - verified August 2014

  • Condition:   High-risk Smoldering Multiple Myeloma
    Interventions:   Drug: Siltuximab;   Drug: Placebo
    Sponsor:   Janssen Research & Development, LLC
    Recruiting - verified September 2014

  • Condition:   Prostate Cancer
    Intervention:   Procedure: Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) imaging
    Sponsor:   University of Wisconsin, Madison
    Recruiting - verified August 2014

  • Condition:   Asthma
    Interventions:   Drug: ADVAIR 100/50mcg;   Drug: ADVAIR 250/50mcg;   Drug: ADVAIR 500/50mcg;   Drug: FLOVENT 100mcg;   Drug: FLOVENT 250mcg;   Drug: FLOVENT 500mcg
    Sponsors:   GlaxoSmithKline;   Parexel
    Recruiting - verified September 2014

  • Condition:   Asthma
    Interventions:   Drug: ADVAIR 100/50mcg;   Drug: ADVAIR 250/50mcg;   Drug: FLOVENT 100mcg;   Drug: FLOVENT 250mcg
    Sponsors:   GlaxoSmithKline;   Parexel
    Recruiting - verified September 2014

  • Condition:   Smoking Cessation
    Interventions:   Drug: Placebo;   Drug: varenicline tartrate;   Drug: bupropion hydrochloride;   Drug: Nicotine Replacement Therapy Patch
    Sponsors:   Pfizer;   GlaxoSmithKline
    Recruiting - verified September 2014

  • Conditions:   Adult Acute Erythroid Leukemia (M6);   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Pure Erythroid Leukemia (M6b);   Childhood Acute Erythroleukemia (M6);   Childhood Acute Megakaryocytic Leukemia (M7);   Childhood Acute Minimally Differentiated Myeloid Leukemia (M0);   Childhood Acute Monoblastic Leukemia (M5a);   Childhood Acute Monocytic Leukemia (M5b);   Childhood Acute Myeloblastic Leukemia With Maturation (M2);   Childhood Acute Myeloblastic Leukemia Without Maturation (M1);   Childhood Acute Myelomonocytic Leukemia (M4);   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
    Interventions:   Drug: asparaginase;   Drug: daunorubicin hydrochloride;   Drug: mitoxantrone hydrochloride;   Drug: sorafenib tosylate;   Drug: cytarabine;   Drug: etoposide;   Drug: bortezomib;   Other: pharmacological study;   Other: laboratory biomarker analysis;   Other: questionnaire administration;   Other: quality-of-life assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Conditions:   Bladder Cancer;   Breast Cancer;   Endometrial Cancer;   Esophageal Cancer;   Head and Neck Cancer;   Lung Cancer;   Melanoma;   Ovarian Neoplasm;   Testicular Lymphoma;   Transitional Cell Cancer of the Renal Pelvis and Ureter;   Unspecified Adult Solid Tumor, Protocol Specific;   Ureter Cancer;   Urethral Cancer
    Interventions:   Drug: veliparib;   Drug: paclitaxel;   Drug: carboplatin;   Other: laboratory biomarker analysis;   Other: pharmacological study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified September 2014

  • Conditions:   Hematologic Malignancies;   Certain:;   Inherited Disorders of Metabolism;   Inherited Abnormalities of Erythrocyte Differentiation or Function;   Inherited Abnormalities of Platelets;   Disorders of the Immune System;   Histiocytic Disorders;   X-linked Adrenoleukodystrophy;   Primary Immunodeficiency Diseases;   Bone Marrow Failure;   Beta-thalassemia
    Intervention:   Drug: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
    Sponsors:   Center for International Blood and Marrow Transplant Research;   National Marrow Donor Program
    Recruiting - verified September 2014

  • Conditions:   Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Male Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
    Interventions:   Drug: veliparib;   Drug: cyclophosphamide;   Other: placebo;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified July 2014

  • Condition:   Chronic Musculoskeletal Pain
    Intervention:   Behavioral: Resistance Exercise Training
    Sponsor:   Department of Veterans Affairs
    Recruiting - verified September 2014

  • Condition:   Non-Small Cell Lung Cancer
    Interventions:   Drug: bevacizumab [Avastin];   Drug: Standard of care treatment
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified September 2014

  • Condition:   Prostate Cancer
    Interventions:   Biological: pTVG-HP;   Biological: rhGM-CSF
    Sponsor:   University of Wisconsin, Madison
    Recruiting - verified August 2014

  • Conditions:   Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   HER2-positive Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer
    Interventions:   Drug: doxorubicin hydrochloride;   Drug: docetaxel;   Drug: cyclophosphamide;   Biological: trastuzumab;   Drug: paclitaxel;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified July 2014

  • Conditions:   Recurrent Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
    Interventions:   Biological: ipilimumab;   Biological: recombinant interferon alfa-2b;   Other: quality-of-life assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified September 2014

  • Conditions:   Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
    Interventions:   Drug: systemic chemotherapy;   Drug: tamoxifen citrate;   Drug: anastrozole;   Drug: exemestane;   Drug: letrozole;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified September 2014

  • Condition:   Herpes Zoster
    Interventions:   Biological: V212;   Biological: Placebo
    Sponsor:   Merck Sharp & Dohme Corp.
    Recruiting - verified September 2014

  • Condition:   Breast Cancer
    Interventions:   Procedure: palliative surgery;   Procedure: therapeutic conventional surgery;   Radiation: palliative radiation therapy;   Radiation: radiation therapy
    Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified September 2014

  • Conditions:   Adult Supratentorial Primitive Neuroectodermal Tumor (PNET);   Childhood Supratentorial Primitive Neuroectodermal Tumor;   Ewing Sarcoma of Bone;   Extraosseous Ewing Sarcoma;   Extraosseous Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Peripheral Primitive Neuroectodermal Tumor of the Kidney;   Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
    Interventions:   Drug: vincristine sulfate;   Drug: doxorubicin hydrochloride;   Drug: cyclophosphamide;   Drug: ifosfamide;   Drug: etoposide;   Drug: topotecan hydrochloride;   Other: laboratory biomarker analysis
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified September 2014

  • Conditions:   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Pineoblastoma;   Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor
    Interventions:   Drug: temozolomide;   Drug: irinotecan hydrochloride;   Biological: bevacizumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified September 2014

  • Conditions:   Recurrent Thyroid Cancer;   Stage I Follicular Thyroid Cancer;   Stage I Papillary Thyroid Cancer;   Stage II Follicular Thyroid Cancer;   Stage II Papillary Thyroid Cancer;   Stage III Follicular Thyroid Cancer;   Stage III Papillary Thyroid Cancer;   Stage IVA Follicular Thyroid Cancer;   Stage IVA Papillary Thyroid Cancer;   Stage IVB Follicular Thyroid Cancer;   Stage IVB Papillary Thyroid Cancer;   Stage IVC Follicular Thyroid Cancer;   Stage IVC Papillary Thyroid Cancer
    Interventions:   Drug: cediranib maleate;   Drug: lenalidomide;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Conditions:   Ovarian Clear Cell Cystadenocarcinoma;   Stage III Ovarian Epithelial Cancer;   Stage IV Ovarian Epithelial Cancer
    Interventions:   Drug: paclitaxel;   Drug: carboplatin;   Drug: temsirolimus;   Drug: docetaxel;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Conditions:   Light Chain Deposition Disease;   Smoldering Multiple Myeloma
    Interventions:   Drug: lenalidomide;   Other: clinical observation;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Condition:   Psoriasis
    Interventions:   Drug: CP-690,550;   Drug: CP-690,550
    Sponsor:   Pfizer
    Recruiting - verified September 2014

  • Conditions:   B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Childhood Acute Lymphoblastic Leukemia;   T-cell Adult Acute Lymphoblastic Leukemia;   T-cell Childhood Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
    Interventions:   Other: laboratory biomarker analysis;   Other: cytology specimen collection procedure
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified September 2014

  • Condition:   Respiratory Distress Syndrome
    Interventions:   Device: Nasal continuous positive airway pressure (nCPAP);   Device: Laryngeal Mask Airway (LMA) to deliver surfactant
    Sponsor:   University of Minnesota - Clinical and Translational Science Institute
    Recruiting - verified September 2014

  • Condition:   Colorectal Cancer
    Interventions:   Biological: cetuximab;   Biological: ramucirumab;   Drug: irinotecan hydrochloride
    Sponsors:   Pam Cogliano;   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group
    Recruiting - verified June 2012

  • Conditions:   Adult Primary Hepatocellular Carcinoma;   Localized Unresectable Adult Primary Liver Cancer;   Recurrent Adult Primary Liver Cancer
    Interventions:   Drug: sorafenib tosylate;   Other: placebo;   Drug: doxorubicin hydrochloride;   Drug: doxorubicin-eluting beads;   Drug: cisplatin;   Drug: mitomycin C;   Other: pharmacological study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Conditions:   Brenner Tumor;   Ovarian Carcinosarcoma;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Primary Peritoneal Cavity Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Primary Peritoneal Cavity Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Primary Peritoneal Cavity Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Primary Peritoneal Cavity Cancer
    Interventions:   Drug: paclitaxel;   Drug: carboplatin;   Biological: bevacizumab;   Drug: veliparib;   Drug: cisplatin;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified August 2014

  • Conditions:   Distal Urethral Cancer;   Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter;   Proximal Urethral Cancer;   Recurrent Bladder Cancer;   Recurrent Prostate Cancer;   Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter;   Recurrent Urethral Cancer;   Regional Transitional Cell Cancer of the Renal Pelvis and Ureter;   Stage IV Bladder Cancer;   Stage IV Prostate Cancer;   Stage IV Urethral Cancer;   Transitional Cell Carcinoma of the Bladder;   Ureter Cancer;   Urethral Cancer Associated With Invasive Bladder Cancer
    Interventions:   Drug: gemcitabine hydrochloride;   Drug: cisplatin;   Other: placebo;   Biological: bevacizumab;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified August 2014

  • Conditions:   Anemia;   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes
    Interventions:   Drug: lenalidomide;   Biological: epoetin alfa;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Condition:   Solid Tumors
    Intervention:   Drug: axitinib
    Sponsor:   Pfizer
    Recruiting - verified September 2014

  • Conditions:   Lymphoma;   Nonneoplastic Condition
    Interventions:   Biological: bleomycin sulfate;   Biological: filgrastim;   Drug: ABVD regimen;   Drug: BEACOPP regimen;   Drug: cyclophosphamide;   Drug: dacarbazine;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: prednisone;   Drug: procarbazine hydrochloride;   Drug: vinblastine sulfate;   Drug: vincristine sulfate
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified September 2014

  • Conditions:   Chemotherapeutic Agent Toxicity;   Childhood Cancer;   Cognitive/Functional Effects;   Neurotoxicity;   Psychosocial Effects of Cancer and Its Treatment;   Radiation Toxicity
    Interventions:   Procedure: psychosocial assessment and care;   Procedure: cognitive assessment;   Other: quality-of-life assessment;   Other: questionnaire administration
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified August 2014

  • Condition:   Ductal Breast Carcinoma in Situ
    Interventions:   Biological: trastuzumab;   Radiation: whole breast irradiation;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Conditions:   Brenner Tumor;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Primary Peritoneal Cavity Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Primary Peritoneal Cavity Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Primary Peritoneal Cavity Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Primary Peritoneal Cavity Cancer
    Interventions:   Behavioral: behavioral dietary intervention;   Behavioral: exercise intervention;   Other: counseling intervention;   Other: educational intervention;   Behavioral: compliance monitoring;   Other: questionnaire administration;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
    Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified September 2014

  • Condition:   Melanoma (Skin)
    Interventions:   Drug: dasatinib;   Other: laboratory biomarker analysis
    Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified September 2014

  • Conditions:   Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Salivary Gland Cancer;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Salivary Gland Squamous Cell Carcinoma;   Stage IV Salivary Gland Cancer;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IVA Salivary Gland Cancer;   Stage IVA Squamous Cell Carcinoma of the Larynx;   Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Verrucous Carcinoma of the Larynx;   Stage IVA Verrucous Carcinoma of the Oral Cavity;   Stage IVB Salivary Gland Cancer;   Stage IVB Squamous Cell Carcinoma of the Larynx;   Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Oropharynx;   Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Verrucous Carcinoma of the Larynx;   Stage IVB Verrucous Carcinoma of the Oral Cavity;   Stage IVC Salivary Gland Cancer;   Stage IVC Squamous Cell Carcinoma of the Larynx;   Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVC Squamous Cell Carcinoma of the Oropharynx;   Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Verrucous Carcinoma of the Larynx;   Stage IVC Verrucous Carcinoma of the Oral Cavity;   Tongue Cancer;   Untreated Metastatic Squamous Neck Cancer With Occult Primary
    Interventions:   Drug: docetaxel;   Drug: cisplatin;   Drug: carboplatin;   Drug: fluorouracil;   Biological: bevacizumab;   Other: laboratory biomarker analysis;   Other: cytology specimen collection procedure
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified August 2014

  • Conditions:   Brenner Tumor;   Fallopian Tube Cancer;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Primary Peritoneal Cavity Cancer;   Recurrent Ovarian Epithelial Cancer
    Interventions:   Drug: paclitaxel;   Drug: docetaxel;   Drug: carboplatin;   Biological: bevacizumab;   Drug: gemcitabine hydrochloride;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified August 2014

  • Condition:   Hypereosinophilic Syndrome
    Intervention:   Drug: mepolizumab
    Sponsor:   GlaxoSmithKline
    Recruiting - verified July 2014

  • Conditions:   Disseminated Neuroblastoma;   Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Regional Neuroblastoma;   Stage 4S Neuroblastoma
    Interventions:   Drug: isotretinoin;   Biological: sargramostim;   Biological: dinutuximab;   Biological: aldesleukin;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment;   Other: pharmacological study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified September 2014

  • Conditions:   Depression;   Mood Disorder;   Anxiety Disorder;   Healthy
    Intervention:  
    Sponsors:   National Institute of Mental Health (NIMH);   University of Minnesota - Clinical and Translational Science Institute;   University of Oregon;   University of Maryland;   National Institutes of Health Clinical Center (CC)
    Recruiting - verified March 2014

PaidClinicalTrials.orgPaidClinicalTrials.org